Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Caitlin E. Cox

April 15, 2024

Presentation ACC 2024

Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (Results of IMPROVE-HCM)

Presenter: Martin S. Maron

April 08, 2024

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

L.A. McKeown

April 06, 2024

News Conference News ACC 2023

STELLAR, ‘Impressive’ Results With Novel Drug Sotatercept in PAH

Shelley Wood

March 06, 2023

News Conference News ACC 2023

BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF

L.A. McKeown

March 06, 2023

Presentation ACC 2023

Impact of Heart Failure Management Using Thoracic Fluid Monitoring From A Novel Wearable Sensor: Results of the Benefits of Microcor (μCor™) in Ambulatory Heart Failure (BMAD) Trial

Presenter: John P. Boehmer

March 05, 2023

News Opinion Editor's Corner ACC 2023

What’s Going to Be Hot at ACC/WCC 2023?

Shelley Wood

February 27, 2023

News Conference News ACC 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

Todd Neale

April 08, 2022

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

Seasonal, but No Year-round, Protection With Flu Shots in HF: IVVE

News Conference News ACC 2022

Seasonal, but No Year-round Help for HF With Flu Shots: IVVE

Yael L. Maxwell

April 03, 2022

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

News Conference News ACC 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

Todd Neale

May 18, 2021

News Conference News ACC 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

L.A. McKeown

May 15, 2021

News Conference News ACC 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

Michael O'Riordan

March 28, 2020

News Daily News ACC 2020

Better QoL After MitraClip Plus Fewer Deaths, HF Hospitalizations: COAPT

Shelley Wood

March 17, 2020

News Conference News ACC 2019

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

Michael O'Riordan

March 25, 2019

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Shelley Wood

March 11, 2019

News Conference News ACC 2018

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

Caitlin E. Cox

March 19, 2018

Advertisement

What’s Going to Be Hot at ACC 2025?

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (Results of IMPROVE-HCM)

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

STELLAR, ‘Impressive’ Results With Novel Drug Sotatercept in PAH

BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF

Impact of Heart Failure Management Using Thoracic Fluid Monitoring From A Novel Wearable Sensor: Results of the Benefits of Microcor (μCor™) in Ambulatory Heart Failure (BMAD) Trial

What’s Going to Be Hot at ACC/WCC 2023?

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Seasonal, but No Year-round Help for HF With Flu Shots: IVVE

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

Better QoL After MitraClip Plus Fewer Deaths, HF Hospitalizations: COAPT

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content